易瑞生物
(300942)
| 流通市值：25.52亿 | | | 总市值：25.52亿 |
| 流通股本：4.05亿 | | | 总股本：4.05亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 128,365,795.09 | 57,644,102.49 | 263,229,020.8 | 185,633,642.05 |
| 营业收入 | 128,365,795.09 | 57,644,102.49 | 263,229,020.8 | 185,633,642.05 |
| 二、营业总成本 | 154,899,413.61 | 73,515,702.11 | 260,412,512.64 | 181,665,643.9 |
| 营业成本 | 52,663,264.27 | 25,480,050.83 | 94,808,397.72 | 66,262,171.88 |
| 税金及附加 | 194,395.83 | 49,654.19 | 1,845,239.94 | 648,235.48 |
| 销售费用 | 33,591,775.5 | 15,914,105.73 | 58,140,944.03 | 42,641,146.45 |
| 管理费用 | 23,542,154.72 | 10,857,448.22 | 46,635,430.58 | 32,813,550.16 |
| 研发费用 | 21,937,457.99 | 9,740,118.82 | 41,446,356.76 | 30,819,335.83 |
| 财务费用 | 22,970,365.3 | 11,474,324.32 | 17,536,143.61 | 8,481,204.1 |
| 其中:利息费用 | 13,509,322.7 | 6,716,880.74 | 26,492,015.63 | 19,676,887.16 |
| 其中:利息收入 | 4,705,439.02 | 1,385,928.52 | 10,213,743.02 | 7,992,244.97 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,132,844.98 | 1,249,384.05 | 2,949,322.7 | 1,681,238.3 |
| 加:投资收益 | -1,494,351 | 77,973.81 | -8,145,643.14 | -3,243,496.93 |
| 资产处置收益 | -119,593.88 | -119,511.16 | 12,214,552.49 | 12,202,445.31 |
| 资产减值损失(新) | -277,170.13 | - | -5,468,180.37 | -149,956.42 |
| 信用减值损失(新) | -2,420,052.83 | -667,516.32 | -4,875,158.47 | -881,293.06 |
| 其他收益 | 3,849,437.05 | 2,186,344.73 | 6,086,506.56 | 3,094,291.45 |
| 四、营业利润 | -23,862,504.33 | -13,144,924.51 | 5,577,907.93 | 16,671,226.8 |
| 加:营业外收入 | 668,534.81 | 55,571.65 | 7,825,634.49 | 407,163.55 |
| 减:营业外支出 | 965,317 | 1,258.5 | 114,636.8 | 89,936.49 |
| 五、利润总额 | -24,159,286.52 | -13,090,611.36 | 13,288,905.62 | 16,988,453.86 |
| 减:所得税费用 | -4,762,515.69 | -2,604,885.66 | -2,177,451.14 | -1,818,666.01 |
| 六、净利润 | -19,396,770.83 | -10,485,725.7 | 15,466,356.76 | 18,807,119.87 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -19,396,770.83 | -10,485,725.7 | 15,466,356.76 | 18,807,119.87 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -19,726,940.71 | -10,259,486.22 | 13,743,333.96 | 18,023,048.35 |
| 少数股东损益 | 330,169.88 | -226,239.48 | 1,723,022.8 | 784,071.52 |
| 扣除非经常损益后的净利润 | -23,544,350.95 | -13,228,469.25 | -9,653,189.87 | 3,728,488.75 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.05 | -0.03 | 0.03 | 0.04 |
| (二)稀释每股收益 | -0.05 | -0.03 | 0.03 | 0.04 |
| 八、其他综合收益 | -444,264.96 | -217,813.54 | 160,162.48 | -108,226.44 |
| 归属于母公司股东的其他综合收益 | -444,264.96 | -217,813.54 | 160,162.48 | -108,226.44 |
| 九、综合收益总额 | -19,841,035.79 | -10,703,539.24 | 15,626,519.24 | 18,698,893.43 |
| 归属于母公司股东的综合收益总额 | -20,171,205.67 | -10,477,299.76 | 13,903,496.44 | 17,914,821.91 |
| 归属于少数股东的综合收益总额 | 330,169.88 | -226,239.48 | 1,723,022.8 | 784,071.52 |
| 公告日期 | 2026-08-28 | 2026-04-27 | 2026-04-27 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |